Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease
NCT05587322 is registered in ClinicalTrials.gov with Braintree Laboratories as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease
- Lead sponsor
- Braintree Laboratories
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 6, 2022
- Completion date
- April 23, 2024
- Enrollment
- 788 (actual)
- Sites
- 112
Conditions
As the registry lists them; a condition with its own page is linked.